Teva Pharmaceutical Industries Ltd., of Jerusalem, received a positive outcome in the decentralized procedure for its new, three-times-a-week Copaxone (glatiramer acetate) 40 mg/ml formulation for the treatment of adults with relapsing forms of multiple sclerosis.